Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder
A Double-blind, Randomised, Placebo-controlled, Multicentre, Relapse-prevention Study With Lu AA21004 in Patients With Generalized Anxiety Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, 1900
- AR010
-
Buenos Aires, Argentina, B1900BHE
- AR012
-
Buenos Aires, Argentina, C1117ABH
- AR002
-
Buenos Aires, Argentina, C1405BOA
- AR008
-
Buenos Aires, Argentina, C1425AHQ
- AR003
-
Buenos Aires, Argentina, C1428AAQ
- AR013
-
Cordoba, Argentina, 5000
- AR004
-
La Plata, Argentina, 1900
- AR015
-
Mendoza, Argentina, M5500BCR
- AR006
-
Mendoza, Argentina, M5502BKH
- AR009
-
Santa Fé, Argentina, S2000QJI
- AR001
-
-
-
-
-
Antofagasta, Chile
- CL004
-
Coquimbo, Chile
- CL001
-
Santiago, Chile
- CL002
-
Santiago, Chile
- CL003
-
Santiago, Chile
- CL005
-
Santiago, Chile
- CL007
-
Santiago, Chile
- CL008
-
Vina del Mar, Chile
- CL006
-
-
-
-
-
Barranquilla, Colombia
- CO003
-
Bogotá, Colombia
- CO001
-
Bogotá, Colombia
- CO005
-
Envigado, Colombia
- CO006
-
Medellin, Colombia
- CO002
-
Medellin, Colombia
- CO007
-
Pareira, Colombia
- CO004
-
-
-
-
-
Escazu, Costa Rica
- CR002
-
Guadalupe, Costa Rica
- CR004
-
San José, Costa Rica
- CR001
-
San Pedro, Costa Rica
- CR003
-
-
-
-
-
Tallinn, Estonia, 10613
- EE001
-
Tallinn, Estonia, 13517
- EE004
-
Tartu, Estonia, 50417
- EE002
-
-
-
-
-
Espoo, Finland, 2650
- FI006
-
Helsinki, Finland, 00260
- FI008
-
Helsinki, Finland, 00530
- FI001
-
Helsinki, Finland, 100
- FI004
-
Helsinki, Finland, 100
- FI011
-
Helsinki, Finland, 99
- FI010
-
Juväskylä, Finland, 40100
- FI005
-
Kuopio, Finland, 70110
- FI012
-
Oulu, Finland, 90100
- FI002
-
Rauma, Finland, 26100
- FI009
-
Turku, Finland, 20100
- FI003
-
Turku, Finland, 20100
- FI007
-
-
-
-
-
Arcachon, France, 33120
- FR011
-
Caen, France, 14000
- FR010
-
Douai, France, 59500
- FR016
-
Nantes, France, 44000
- FR012
-
Nîmes, France, 30029
- FR004
-
Palaiseau, France, 91120
- FR013
-
Rennes, France, 35000
- FR007
-
Saint-André-de-Cubzac, France, 33240
- FR001
-
Strasbourg, France, 67000
- FR002
-
Toulouse, France, 31000
- FR015
-
Toulouse, France, 31200
- FR005
-
-
-
-
-
Budapest, Hungary, 1036
- HU005
-
Budapest, Hungary, 1095
- HU004
-
Budapest, Hungary, 1135
- HU002
-
Gyula, Hungary, 5700
- HU001
-
Nagykallo, Hungary, 4320
- HU006
-
Sopron, Hungary, 9400
- HU008
-
-
-
-
-
Lima, Peru, 27
- PE003
-
Lima, Peru, 41
- PE002
-
-
-
-
-
Chita, Russian Federation, 672090
- RU004
-
St. Petersburg, Russian Federation, 192019
- RU006
-
St. Petersburg, Russian Federation, 193019
- RU002
-
St. Petersburg, Russian Federation, 193019
- RU003
-
Tomsk, Russian Federation, 634014
- RU001
-
-
-
-
-
Bloemfontein, South Africa, 9033
- ZA006
-
Cape Town, South Africa, 1
- ZA004
-
Cape Town, South Africa, 7130
- ZA011
-
Cape Town, South Africa, 7130
- ZA012
-
Cape Town, South Africa, 7140
- ZA003
-
Cape Town, South Africa, 7620
- ZA010
-
Gauteng, South Africa, 157
- ZA007
-
Gauteng, South Africa, 2195
- ZA001
-
Gauteng, South Africa, 7500
- ZA009
-
Kempton Park, South Africa, 1620
- ZA002
-
KwaZulu Natal, South Africa, 3630
- ZA008
-
Welkom, South Africa, 9459
- ZA005
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The patient has GAD as the primary diagnosis according to DSM-IV-TR criteria (classification code 300.02).
- The patient has a HAM-A total score >=20 at screening and baseline visits
- The patient has a HAM-A score >=2 on both Item 1 (anxious mood) and Item 2 (tension) at screening and baseline visits
- The patient has a MADRS total score <=16 at screening and baseline visits
Exclusion Criteria:
- Any current psychiatric disorder other than GAD as defined in the DSM-IV-TR (assessed with the MINI)
- Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR
- Women of childbearing potential not using effective contraception
Other protocol-defined inclusion and exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Once daily
|
|
Experimental: Lu AA21004
|
5 or 10 mg/day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to relapse
Time Frame: At least 24 weeks
|
At least 24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Relapse rates, Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impression Scale (CGI), MOS SF-36, Sheehan Disability Scale (SDS), Adverse events, Clinical laboratory tests, Vital signs, ECG
Time Frame: At least 24 weeks
|
At least 24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Christensen MC, Loft H, Florea I, McIntyre RS. Efficacy of vortioxetine in working patients with generalized anxiety disorder. CNS Spectr. 2019 Apr;24(2):249-257. doi: 10.1017/S1092852917000761. Epub 2017 Oct 30. Erratum In: CNS Spectr. 2019 Apr;24(2):275.
- Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012 Jul;27(4):197-207. doi: 10.1097/YIC.0b013e3283530ad7.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Disease Attributes
- Anxiety Disorders
- Recurrence
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin Antagonists
- Anti-Anxiety Agents
- Serotonin 5-HT3 Receptor Antagonists
- Vortioxetine
Other Study ID Numbers
Other Study ID Numbers
- 12473A
- 2008-001673-15 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.